Inozyme Pharma company information, Employees & Contact Information

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders GlobeNewswire

Inozyme Pharma Postpones 2025 Annual Meeting of Stockholders Amid BioMarin Acquisition Discussions Quiver Quantitative

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients Contemporary Pediatrics

BioMarin to buy rare disease drugmaker Inozyme for $270M BioPharma Dive

BioMarin's $270M Acquisition Brings First-Ever Treatment for Fatal Childhood Bone Disease to Phase 3 Stock Titan

As M&A slows, Boston’s biotech sector stands out Capital Analytics Associates

BioMarin Expands Enzyme Expertise With $270M Inozyme Buy BioSpace

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era Fierce Biotech

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year Contemporary Pediatrics

Inozyme Pharma Reports Full Year 2024 Financial Results and GlobeNewswire

BioMarin agrees to acquire Inozyme for $270m Pharmaceutical Technology

FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701, a Treatment for Patients with ABCC6 Deficiency Pharmaceutical Executive

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz Yahoo Finance

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease MedCity News

BioMarin completes $270 million acquisition of Inozyme Pharma Investing.com

Katie Swanner The Business Journals

Leerink bullish on BioMarin following Inozyme deal, expects additional BD Yahoo Finance

Inozyme Pharma Announces Positive Interim Data for INZ-701 GlobeNewswire

Inozyme Pharma to Present at Upcoming Investor Conferences Yahoo Finance

BioMarin Completes Acquisition of Inozyme Pharma for $270M Contract Pharma

Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders Business Wire

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks Yahoo Finance

Soojin Kim The Business Journals

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A Genetic Engineering and Biotechnology News

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease Stock Titan

Dollar Stock Skyrockets 179% On BioMarin Takeover Investor's Business Daily

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) Seeking Alpha

Inozyme puts faith in Petra Duda as new CMO The Pharma Letter

BioMarin buys Inozyme for $270 million The Pharma Letter

Cooley, Goodwin Build BioMarin's $270M Inozyme Buy Law360

Ruth du Moulin The Business Journals

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? simplywall.st

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) Seeking Alpha

BioMarin stock in focus on M&A deal with Inozyme (BMRN:NASDAQ) Seeking Alpha

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus Pharma Voice

INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice Wiley Online Library

Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition TipRanks

Annexon, Inozyme, iTeos snag $564M in upsized IPOs Fierce Biotech

Sanofi, Novo back rare disease startup Inozyme in $49M round Fierce Biotech

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire